Effective Mood Stabilization With a Chelated Mineral Supplement: An Open-Label Trial in Bipolar Disorder
J Clin Psychiatry 2001;62(12):936-944
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: To determine in open trials the therapeutic benefit
of a nutritional supplement for bipolar disorder.
Method: The sample consisted of 11 patients with DSM-IV-diagnosed
bipolar disorder aged 19 to 46 years, who were taking a mean of 2.7 psychotropic
medications each at study entry. Three additional patients dropped out prematurely.
The intervention is a broad-based nutritional supplement of dietary nutrients,
primarily chelated trace minerals and vitamins, administered in high doses.
At study entry and periodically thereafter, patients were assessed with the
Hamilton Rating Scale for Depression (HAM-D), the Brief Psychiatric Rating Scale
(BPRS), and the Young Mania Rating Scale (YMRS).
Results: For those who completed the minimum 6-month open trial,
symptom reduction ranged from 55% to 66% on the outcome measures; need for psychotropic
medications decreased by more than 50%. Paired t tests revealed treatment benefit
on all measures for patients completing the trial: HAM-D mean score at entry
= 19.0, mean score at last visit = 5.4, t = 5.59, df = 9, p < .01; BPRS mean
score at entry = 35.3, mean score at last visit = 7.4, t = 2.57, df = 9, p <
.05; YMRS mean score at entry = 15.1, mean score at last visit = 6.0, t = 4.11,
df = 9, p < .01. The effect size for the intervention was large (> .80)
for each measure. The number of psychotropic medications decreased significantly
to a mean ± SD of 1.0 ± 1.1 (t = 3.54, df = 10, p < .01). In
some cases, the supplement replaced psychotropic medications and the patients
remained well. The only reported side effect (i.e., nausea) was infrequent,
minor, and transitory.
Conclusion: Some cases of bipolar illness may be ameliorated
by nutritional supplementation. A randomized, placebo-controlled trial in adults
with bipolar I disorder is currently underway, as well as open trials in children.